NEW YORK, January 15, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Co. (NYSE: BMY), Amgen, Inc. (NASDAQ: AMGN), St. Jude Medical, Inc. (NYSE: STJ), Boston Scientific Corporation (NYSE: BSX), and Mylan Inc. (NASDAQ: MYL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Bristol-Myers Squibb Co. Research Report
On January 8, 2014, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) announced that the European Medicines Agency (EMA) has validated the Company's marketing authorization application (MAA) for the use of daclatasvir (DCV), an investigational NS5A complex inhibitor, for the treatment of adults with chronic hepatitis C (HCV) with compensated liver disease, including genotypes 1, 2, 3, and 4. According to Bristol-Myers Squibb, the application seeks the approval of daclatasvir to be used in combination with other agents, including sofosbuvir, for the treatment of chronic hepatitis C. The Company also informed that this MAA validation is the beginning of an accelerated regulated review process for DCV. Brian Daniels, MD, Senior Vice President, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb, commented, "If daclatasvir is approved, we would focus on helping to ensure its availability to patients with limited treatment options and would work with EU health authorities to ensure access is achieved as quickly as possible." The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Amgen, Inc. Research Report
On January 9, 2014, Amgen, Inc. (Amgen) announced that Executive Vice President and CFO, Jonathan M. Peacock, is leaving the Company in order to pursue broader career opportunities. According to Amgen, Peacock steps down as CFO effective January 10, 2014, and the Company expects him to remain employed with Amgen until May 2014 to help in the transition. The Company added that Michael A. Kelly has been named acting CFO, with reporting to Robert A. Bradway, Chairman and CEO. Bradway commented, "Since joining Amgen over three years ago, Jon has played an important role in developing and implementing the company's strategy for growth and in delivering value for shareholders. We thank Jon for his many contributions and fully support his desire to pursue broader opportunities." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
St. Jude Medical, Inc. Research Report
On January 10, 2014, St. Jude Medical, Inc. (St. Jude Medical) announced that the Company will hold a conference call to discuss its Q4 2013 and full-year 2013 financial results on January 22, 2014 at 8:00 a.m. EST (7:00 a.m. CST). The Company said that a live webcast of the call will be available on the Investor Relations section of its website, where a replay will be also available approximately one hour after the call. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Boston Scientific Corporation Research Report
On January 6, 2014, Boston Scientific Corporation (Boston Scientific) announced that Craig Thompson, M.D., has been appointed as Senior Vice President and Chief Medical Officer, Interventional Cardiology, effective immediately. The Company added that Dr. Thompson has previously held the roles of Director, Invasive Cardiology and Vascular Medicine, Yale New Haven Hospital, and Associate Professor of Medicine, Yale University School of Medicine. Kevin Ballinger, President, Interventional Cardiology, Boston Scientific, stated, "Craig is a very experienced interventional cardiologist who is an important addition to our clinical team, increasing our ability to innovate medical solutions that provide unique value to physicians and patients." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Mylan Inc. Research Report
On January 9, 2014, Mylan Inc. (Mylan) announced that Zyomyx's MyT4™ point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, marking an important step towards launching the test. According to the Company, the MyT4™ CD4 test can now bear the CE mark, which shows its compliance with stringent requirements of quality, safety, and performance of in vitro medical devices found in the applicable EU laws. Mylan informed it has an exclusive distribution agreement with Zyomyx, the manufacturer of MyT4™. Commenting on the results, Mylan CEO Heather Bresch said, "Mylan is proud to continue its commitment to setting new standards in health care by collaborating with Zyomyx on their MyT4™ test. The CE Mark for the MyT4™ test testifies to the exacting quality, safety and performance of this important diagnostic tool and we look forward to begin distributing it in the coming months." The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner